Stealth BioTherapeutics’ elamipretide infusion improves kidney microvasculature in phase 2 trial

The phase 2 trial, dubbed Evolve, involved 14 patients ages 40 to 80 years who were undergoing percutaneous transluminal renal angioplasty and stenting.

The study's endpoints were a change in kidney function, blood flow and perfusion to the kidney which were all met during the trial at satisfactory levels according to the biopharma company.

The patients were given a single intravenous dose of either elamipretide or placebo prior to the procedure.
Findings of the trial revealed that patients subjected to elamipretide had their renal function significantly improve three months post procedure.

On the other hand, patients who were given placebo did not show any significant change in their renal function measurements, three months after the procedure.

The trial showed that significant improvement was recorded in kidney blood flow at three months only in the patients who were subjected to elamipretide.

Another end point, cortical perfusion was also demonstrated to be improved only in the elamipretide group.

Patients subjected to the investigational drug, were also found to be shielded from a temporary slowdown of oxygen supply to kidney tissue which otherwise developed 24 hours post procedure in the placebo group.

Stealth BioTherapeutics CEO Reenie McCarthy said: “These results provide further evidence of elamipretide’s potential to address mitochondrial dysfunction and restore cellular function across organ systems in both rare diseases and common diseases of aging.

“We are especially encouraged by this data in the context of our broader cardiorenal program, which includes three ongoing Phase 2 trials evaluating the potential of elamipretide to restore tissue function in heart failure."